Journal
TRANSLATIONAL RESEARCH
Volume 179, Issue -, Pages 126-138Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.trsl.2016.07.016
Keywords
-
Categories
Funding
- National MS Society [CA 1027A1/3]
- National Institutes of Health [R41 AI110170/AI/NIAID, R56 AI098282/AI/NIAID]
- Sanofi-Genzyme Corporate (Genzyme/IST Concept Award) [GF-2014-11153]
Ask authors/readers for more resources
There is considerable interest in trying to understand the importance of the gut microbiome in human diseases. The association between dysbiosis, an altered microbial composition, as related to human disease is being explored in the context of different autoimmune conditions, including multiple sclerosis (MS). Recent studies suggest that MS affects the composition of the gut microbiota by altering the relative abundances of specific bacteria and archaea species. Remarkably, some of the bacterial species shown reduced in the gut of MS patients are known to promote immunosuppressive regulatory T cells (Tregs). In MS, the function of a phenotype of Tregs that express CD39, an ectoenzyme involved in the catabolism of adenosine triphosphate as immunomodulatory cells, appears to be reduced. In this review, we discuss the involvement of the gut microbiota in the regulation of experimental models of central nervous system inflammatory demyelination and review the evidence that link the gut microbiome with MS. Further, we hypothesize that the gut microbiome is an essential organ for the control of tolerance in MS patients and a potential source for safer novel therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available